NCT03430856View on ClinicalTrials.gov

Comparison of Insulin Tregopil (IN-105) With Insulin Aspart in Type 2 Diabetes Mellitus Patients

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

December 26, 2017

Primary Completion Date

February 6, 2019

Study Completion Date

February 20, 2019

Conditions
Type2 Diabetes Mellitus
Interventions
DRUG

Insulin Tregopil

Drug: Insulin Tregopil (IN-105) Mode of Administration: To be administered orally 10 ± 2 minutes prior to each major meal (breakfast, lunch and dinner) starting at the Randomization visit.

DRUG

Insulin Aspart

Drug: Insulin Aspart Mode of Administration: To be administered within 5 minutes prior to each major meal (breakfast, lunch and dinner) starting at the Randomization visit

Trial Locations (1)

560010

Diacon Hospital, Bangalore

All Listed Sponsors
lead

Biocon Limited

INDUSTRY

NCT03430856 - Comparison of Insulin Tregopil (IN-105) With Insulin Aspart in Type 2 Diabetes Mellitus Patients | Biotech Hunter | Biotech Hunter